Nkọwa
A na-akpọkwa etiti tofacitinib dị ka cis-1-benzyl-4-methyl-3-methylaminoperidine dihydrochloride ma nwee nọmba CAS 1062580-52-2.Ihe dị n'etiti bụ isi ihe na-emepụta tofacitinib, ọgwụ a na-eji agwọ ọrịa ogbu na nkwonkwo, ọrịa ogbu na nkwonkwo psoriatic na ulcerative colitis.Dị ka ndị isi etiti na njikọ nke tofacitinib, ngwaahịa anyị dị mkpa maka ndị na-eme nchọpụta ọgwụ na ndị na-emepụta ọgwụ.
A na-eji nlezianya na-arụ ọrụ nke etiti a iji hụ na ịdị ọcha na ịdị n'otu kachasị elu.Site na usoro nrụpụta ọgbara ọhụrụ anyị na usoro njikwa mma siri ike, ị nwere ike ịtụkwasị obi na ndị etiti tofacitinib anyị na-ezute ụkpụrụ ụlọ ọrụ kachasị elu maka ịdị ọcha na nkwụsi ike.
Tofacitinib Intermediate (3R, 4R) -1-Benzyl-3- (Mmethylamino) -4-Mmethylpiperidine DiHClide nwere ọtụtụ ngwa ngwa, na-eme ka ọ bụrụ ihe bara uru na nyocha ọgwụ na ọgwụ.Ma ị na-eme nchọpụta agụmakwụkwọ ma ọ bụ na-emepụta ọgwụ, ogige etiti anyị na-enye ngwọta a pụrụ ịdabere na ya na nke bara uru maka mkpa gị.
Họrọ Anyị
JDK nwere ụlọ nrụpụta klaasị mbụ yana akụrụngwa njikwa ogo, nke na-emesi nnabata nke etiti API kwụsiri ike.Ndị otu ọkachamara na-emesi R&D obi ike maka ngwaahịa a.megide abụọ, anyị na-achọ CMO & CDMO n'ime ụlọ na mba ahịa.